Yunzhi Essence

Phase 2Small molecule

CChinese University of Hong Kong

Yunzhi Essence is one of 5 small molecule programs targeting Palliative Care. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Palliative CareRecruiting

Palliative CarePhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Palliative Care

#DrugCompanyPhaseTrials

Psilocybin

COMPASS Pathways

Phase 2

1 2

Lysergic Acid Diethylamide Tartrate

RRigshospitalet, Denmark

Phase 2

1 3

Fscbd Cannabidiol

UUniversity of Colorado, Boulder

Phase 2

1 4

Bscbd Cannabidiol

UUniversity of Colorado, Boulder

Phase 2

1 5

Yunzhi Essence

CChinese University of Hong Kong

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Palliative Care

NCT05754801

Clinical

Trials by Indication[1]

Palliative Care1 trial

Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer: A Randomized, Double-blinded, Placebo-controlled Trial

Recruiting·CChinese University of Hong Kong·Phase 2·NCT05754801·172 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Yunzhi Essence. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yunzhi Essence compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yunzhi Essence. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chinese University of Hong Kong company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChinese University of Hong Kong

Yunzhi Essence

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Palliative Care1 trial

References

Drug Info

Quick Facts

Related News